Your browser doesn't support javascript.
loading
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
Gozgit, Joseph M; Vasbinder, Melissa M; Abo, Ryan P; Kunii, Kaiko; Kuplast-Barr, Kristy G; Gui, Bin; Lu, Alvin Z; Molina, Jennifer R; Minissale, Elena; Swinger, Kerren K; Wigle, Tim J; Blackwell, Danielle J; Majer, Christina R; Ren, Yue; Niepel, Mario; Varsamis, Zacharenia A; Nayak, Sunaina P; Bamberg, Ellen; Mo, Jan-Rung; Church, W David; Mady, Ahmed S A; Song, Jeff; Utley, Luke; Rao, Patricia E; Mitchison, Timothy J; Kuntz, Kevin W; Richon, Victoria M; Keilhack, Heike.
Afiliação
  • Gozgit JM; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA. Electronic address: jgozgit@ribontx.com.
  • Vasbinder MM; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Abo RP; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Kunii K; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Kuplast-Barr KG; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Gui B; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Lu AZ; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Molina JR; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Minissale E; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Swinger KK; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Wigle TJ; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Blackwell DJ; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Majer CR; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Ren Y; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Niepel M; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Varsamis ZA; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Nayak SP; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Bamberg E; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Mo JR; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Church WD; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Mady ASA; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Song J; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Utley L; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Rao PE; Patricia E. Rao Consulting, Acton, MA 01720, USA.
  • Mitchison TJ; Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Warren Alpert 536, Boston, MA 02115, USA.
  • Kuntz KW; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Richon VM; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Keilhack H; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA. Electronic address: hkeilhack@ribontx.com.
Cancer Cell ; 39(9): 1214-1226.e10, 2021 09 13.
Article em En | MEDLINE | ID: mdl-34375612
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferon Tipo I / Resistencia a Medicamentos Antineoplásicos / Proteínas de Transporte de Nucleosídeos / Bibliotecas de Moléculas Pequenas / Neoplasias Limite: Animals / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferon Tipo I / Resistencia a Medicamentos Antineoplásicos / Proteínas de Transporte de Nucleosídeos / Bibliotecas de Moléculas Pequenas / Neoplasias Limite: Animals / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article